Incidences of cGVHD. Incidence of moderate or severe cGVHD at 1 year during clinical trial follow-up (that is, until event as defined in “Methods” or drug suspension occurred) (A) and during the extended 2-year follow-up (B). (C) Incidence of overall cGVHD. (D) Moderate or severe GRFS. The cumulative incidence of cGVHD was performed using Kaplan-Meier analysis, and statistical significance was determined using the log-rank (Mantel-Cox) test.